489 used data on 541 women in the Danish Breast Cancer Cooperative Group registry with recurrent or contralateral estrogen receptor ER positive breast cancer who were treated with tamoxifen and 300 women with ER negative breast cancer who were never treated with tamoxifen priligy seratonin However, this varies from person to person